TG-C (Invossa)

About Kolon TissueGene

Kolon TissueGene's mission is to develop disease-modifying cell and gene therapies that address the root cause of degenerative orthopedic conditions, starting with osteoarthritis (OA) of the knee. Its core achievement is the advancement of TG-C, an off-the-shelf, genetically modified allogeneic chondrocyte therapy, into late-stage global clinical trials. The company's strategy leverages its proprietary platform to create a sustainable, localized therapeutic effect within the joint, aiming to fill a significant unmet need for a disease-modifying OA drug (DMOAD). With strategic backing from its parent conglomerate and a public listing in South Korea, Kolon TissueGene is positioned to navigate the complex path to potential commercialization.

Therapeutic Areas

Other Osteoarthritis of the Knee Drugs